

ASX/Media Release

27 June 2018

Completion of Placement

- Botanix has issued 72.7m shares at an issue price of A\$0.11 per share raising A\$8m (before costs)
- Funds raised will be used to accelerate clinical development of BTX 1204 and progress other key pipeline products

Philadelphia PA and Sydney Australia, 27 June 2018: Further to the ASX announcement on 20 June 2018, Botanix Pharmaceuticals Limited (ASX:BOT, “Botanix” or the “Company”) is pleased to announce that it has today issued a total of 72,727,273 shares at an issue price of A\$0.11 raising approximately A\$8m (before costs) via an oversubscribed placement (“Placement”).

The funds raised under the Placement will be used to advance BTX 1204 into a Phase 2 atopic dermatitis clinical trial, develop BTX 1801 into pilot clinical study and Phase 1b study.

The total dilution of the Placement can be demonstrated as follows:

	Shares	%
Number of shares on issue prior to Placement	684,697,385	90.4
Dilution as a result of issue under the Placement	72,727,273	9.6
Number of shares on issue following Placement	757,424,658	100.0

An Appendix 3B applying for quotation of the Placement shares, together with a cleansing notice in respect of the Placement shares pursuant to section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act) has been lodged with ASX.

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a clinical stage medical dermatology company based in Perth, Australia and Philadelphia, PA. The Company’s focus is the development of safe and effective topical treatments for acne, psoriasis, atopic dermatitis and other skin conditions. The active ingredient contained in Botanix products is a synthetic form of a widely studied natural compound. Treatment targets include inflammation, deterioration of the of the skin barrier, skin cell proliferation, pruritus (itch), excess sebum production and bacterial infection.



Botanix has an exclusive license to use a proprietary drug delivery system (Permetrex™) for direct skin delivery of active pharmaceuticals in all skin diseases. Botanix is working with multiple parties to test the application of Permetrex™ on both a fee-for-service and traditional license basis.

Botanix pursues a rapid clinical development strategy aimed at accelerating product commercialisation. The patient treatment duration of clinical studies is generally completed within a 4 to 12 week timeframe.

The Company completed its first acne patient studies with BTX 1503 in January 2018 and has commenced a Phase 2 clinical trial in June 2018 with completion expected in mid-2019. The Phase 1b BTX 1204 atopic dermatitis patient study concluded in June 2018 and preparation is underway for a Phase 2 clinical trial. A further Phase 1b BTX 1308 psoriasis patient study is also scheduled to commence in 3Q CY2018.

To learn more please visit: <https://www.botanixpharma.com/>

For more information, please contact

General enquiries

Matt Callahan
Botanix Pharmaceuticals
Executive Director
+1 215 767 4184
mcallahan@botanixpharma.com

Investor enquiries

Joel Seah
Vesparum Capital
P: +61 3 8582 4800
botanixpharma@vesparum.com

Media enquiries

Julia Maguire
The Capital Network
P: +61 419 815 386
julia@thecapitalnetwork.com.au